Trial · NCT02667275

A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis

NCT02667275, Phase 3, Completed, Aclaris Therapeutics, Inc.; results first posted 2017-11-13

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis. Trials, record NCT02667275. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02667275

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis
NCT number: NCT02667275
Status: Completed
Phases: Phase 3
Enrollment: 487 participants, actual
Lead sponsor: Aclaris Therapeutics, Inc.
Conditions: Seborrheic Keratosis
Interventions: A-101 Solution, Vehicle Solution
First posted: 2016-01-28
Last updated: 2018-02-06
Results first posted: 2017-11-13

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Proportion of Subjects With All Target Lesions Cleared According to Physician Lesion Assessment Scale	Study day 106	Proportion of subjects for whom all target lesions were judged to be clear on the Physician Lesion Assessment Scale (PLA=0) at Visit 8. The Physician Lesion Assessment Scale is a 4 point scale used by the investigator to assess the subject's target sk lesions.
Secondary	Percent of Lesions Cleared Scale	Study day 106	Proportion of Subjects for whom at least 3 of 4 target lesions were judged to be clear on the Physician Lesion Assessment Scale (PLA=0) at Visit 8

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Proportion of Subjects With All Target Lesions Cleared According to Physician Lesion Assessment Scale	Study day 106		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Percent of Lesions Cleared Scale	Study day 106		Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Proportion of Subjects With All Target Lesions Cleared According to Physician Lesion Assessment Scale	A-101 Solution	19	Participants
Proportion of Subjects With All Target Lesions Cleared According to Physician Lesion Assessment Scale	Vehicle Solution	0	Participants
Percent of Lesions Cleared Scale	A-101 Solution	56	Participants
Percent of Lesions Cleared Scale	Vehicle Solution	0	Participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	A-101 Solution	244
Overall Study	STARTED	Vehicle Solution	243
Overall Study	COMPLETED	A-101 Solution	233
Overall Study	COMPLETED	Vehicle Solution	228
Overall Study	NOT COMPLETED	A-101 Solution	11
Overall Study	NOT COMPLETED	Vehicle Solution	15

Source ClinicalTrials.gov

Adverse events34

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Sinusitis	Infections and infestations	A-101 Solution	4	244	4
other	Sinusitis	Infections and infestations	Vehicle Solution	4	243	4
other	Nasopharyngitis	Infections and infestations	A-101 Solution	1	244	1
other	Nasopharyngitis	Infections and infestations	Vehicle Solution	3	243	3
other	Herpes Zoster	Infections and infestations	A-101 Solution	3	244	3
other	Herpes Zoster	Infections and infestations	Vehicle Solution	0	243	0
serious	Angina Pectoris	Cardiac disorders	A-101 Solution	1	244	1
serious	Angina Pectoris	Cardiac disorders	Vehicle Solution	0	243	0
serious	Sinus Node Dysfunction	Cardiac disorders	A-101 Solution	1	244	1
serious	Sinus Node Dysfunction	Cardiac disorders	Vehicle Solution	0	243	0

1 to 10 of 34Source ClinicalTrials.gov

See all 34 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	A-101 Solution	0	244
Total, all-cause mortality	Vehicle Solution	0	243
Total, other adverse events	A-101 Solution	8	244
Total, other adverse events	Vehicle Solution	7	243
Total, serious adverse events	A-101 Solution	6	244
Total, serious adverse events	Vehicle Solution	4	243

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
30365590	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons4

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
A-101 Solution vs Vehicle Solution: Percent of Lesions Cleared Scale	Trial comparisons
A-101 Solution vs Vehicle Solution: Proportion of Subjects With All Target Lesions Cleared According to Physician Lesion Assessment Scale	Trial comparisons
A-101 Solution vs Vehicle Solution: deaths from any cause	Trial comparisons
A-101 Solution vs Vehicle Solution: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02667275

GET https://conductscience.org/api/trials/v1/NCT02667275/events?page=2

API reference For AI assistants